Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.

Study findings

The authors reported improved motor recovery and reduced oxidative stress and pyroptosis. Experiments proposed an Oprm1–USP18–FTO pathway.

Population and setting

Female mice with spinal-cord injury; supporting cellular experiments

Evidence type

Animal / experimental

Preparation

See the original report; formulation details require verification.

Source language

eng

Title source

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

Study limitations

• Spinal-cord injury is distinct from cerebral stroke.
• Results in female mice and cells do not establish human recovery or safety.
• The proposed receptor pathway requires independent confirmation.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Source access and review scope

Indexed record and abstract checked. Full methods and risk of bias have not been independently assessed.

Recorded source-check date: 2026-10-06. This date does not imply a completed systematic review.

Open original source or index record ↗

DOI: 10.1111/bph.70122

Citation and original source

Original source: Liu R, Chen Y, Huang H, Li X, Lv J, Jiang L, Jiang H, Wu C, Chen W, Xu H, Zhu Z, Cai H, Xiao J, Yin L, Ni W. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British journal of pharmacology; 2025 Nov 2025.

Molekul research summary: https://molekul.io/research/recent-40692165. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles